Eisai Seeks To End Aricept Deal With Pfizer Once Wyeth Acquired
This article was originally published in PharmAsia News
Executive Summary
Eisai is considering an end to its co-promotion deal with U.S.-based Pfizer for the Japanese drug maker's Aricept (donepezil) for treating Alzheimer's Disease. Eisai has not disclosed its plans, but Pfizer said in a regulatory filing it intended to fight Eisai's plan to take back the drug once Pfizer's purchase of fellow U.S. drug maker Wyeth is completed. Pfizer said Eisai has no legal basis for ending the partnership for co-promoting the $482 million-a-year drug. In the filing, Pfizer said Eisai indicated it had the right to end the contract. (Click here for more - a subscription may be required